- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04900103
Evaluation of Implementation of ITV-Pal Program (ITV-Pal)
Evaluation of Implementation Process of Tech-Volunteer Program in Palliative Care: ITV-Pal Program
How can offer support to patients and families through a volunteer caring program based on new technologies? The aim of this study is to implement and evaluate a volunteer training programme in the use of new technologies: ITV-Pal Programme to support patients facing a life-threatening illness and their families.
It will created two groups of volunteers, one group will follow the CUDECA standard training program, the other will follow the proposed intervention, ITV-Pal programme. Volunteers will be allocated randomly to each group. Second stage will consist in the implementation of the direct support to patients and families through the volunteers.
The expectation is that ITV-Pal volunteers trained will be able to increase general welfare of patients and families they care for. To test it, the quality of life of patients, families and volunteers, the quality of the dying process, and identify how new technology supports volunteer end of life care will be measure.
Study Overview
Detailed Description
The inclusion of volunteers to the Team in the care of the patient and the family is continually increasing. The requests for volunteers by the Medical Care Teams have been increasing year after year by 5%, reaching about 75 requests received in 2019. 85% of these requests are assigned a volunteer and the 15% who are not assigned is because the volunteer does not have the required profile which responds to the patient's needs. These statistics show, on the one hand, the important and irreplaceable work that volunteers offer in social support to the patient and this is perceived both by the patient and their family who decide to have it, and also by the Care Team that is aware of the benefits of "non-professional" care, which also humanises palliative care. On the other hand, the volunteer is increasingly present in our society and this is positive, so that more people offer their collaboration and this in turn "normalises" their role in palliative care.
Although volunteers contribute millions of hours of work, the review of bibliography found no sufficiently robust studies to merit inclusion, and even less when associating PC volunteering and NT. As more research is needed on the impact of training and support for palliative care volunteers, this study intends to study the state of art of technophilia and technophobia among patients, relatives, volunteers and healthcare professionals in PC, and according to the results, implement and evaluate a volunteer training programme in the use of new technology to support patients dying at home and their relatives.
The best approach to evaluate the implementation process of complex intervention is the combination of quantitative and qualitative methods. Basic quantitative measures of implementation may be combined with in-depth qualitative data to provide detailed understandings of intervention functioning on a small scale. Use quantitative methods to measure key process variables and allow testing of pre-hypothesised mechanisms of impact and contextual moderators. Use qualitative methods to capture emerging changes in implementation, experiences of the intervention and unanticipated or complex causal pathways, and to generate new theory.
Quantitative approach:
- Pragmatic cluster randomized clinical trial to test the efficacy (the unit of randomization is the volunteer and the unit of analysis is the patient/relative).
- Before-after design for satisfaction of volunteers and HPC with the intervention and its implementation to test the effectiveness.
- Cost-utility study from the perspective of the funder with a time horizon of one year. A detailed cost analysis including costs for the adaptation of volunteer standard course to ITVPal Programme as well as the recruitment and training costs of the volunteers will be performed.
Qualitative approach: interviews (individuals and groupal) with HPC, volunteers and with key informants of patients/relatives to test at the beginning the need and usefulness of NT, and also during the implementation process to test changes and experiences.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pilar Barnestein-Fonseca, PhD
- Phone Number: +34657201115
- Email: pilarbarnestein@cudeca.org
Study Locations
-
-
Málaga
-
Benalmádena, Málaga, Spain, 29631
- Recruiting
- Fundación CUDECA
-
Contact:
- Pilar Barnestein-Fonseca, PhD
- Phone Number: +34657201115
- Email: pilarbarnestein@cudeca.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients/relatives:
- Over 18 years; PC patients and relatives eligible for volunteer support according to the PC team assessment.
- Acceptance to participate in the study by signing the Informed Consent.
PC Volunteers:
- Acceptance to participate in the study by signing the Informed Consent.
Exclusion criteria
- No acceptance to participate in the study by signing the Informed Consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tech-volunteer
A complex intervention with two phases is proposed.
|
Use of new technologies for volunteering
|
No Intervention: Usual volunteer
the control group will receive standard volunteer service.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distress thermometer
Time Frame: Through study completion, an average of 3 months
|
Distress is an unpleasant experience of a mental, physical, social, or spiritual nature.
It can affect the way you think, feel, or act.
Distress may make it harder to cope with having cancer, its symptoms, or its treatment.
0 no distress 10 extreme distress
|
Through study completion, an average of 3 months
|
ICECAP-SCM
Time Frame: Through study completion, an average of 15 days
|
The ICECAP Supportive Care Measure (ICECAP-SCM) has been developed as a tool for use in economic evaluation conducted in an end of life setting
|
Through study completion, an average of 15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EuroQoL 5D-5L
Time Frame: Baseline, 15 and 30 days after inclusion.
|
Quality of life. five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. to describe and value health across a wide range of disease areas. They are also frequently used in research into health in the general population. |
Baseline, 15 and 30 days after inclusion.
|
Satisfaction Volunteer Programme
Time Frame: Through study completion, an average of 12 months
|
Satisfaction with Volunteer Programme by a self develop questionaire
|
Through study completion, an average of 12 months
|
Service Improvement Metrics: fidelity
Time Frame: Through study completion, an average of 12 months
|
Success of the Infrastructure. Whether the intervention was delivered as intended: Referral criteria/identification of patients. |
Through study completion, an average of 12 months
|
Service Improvement Metrics: dose
Time Frame: Through study completion, an average of 12 months
|
Eligibility and take up of the service.
The quantity of intervention implemented: Number of patients eligible for the service and number of patients who accept the service.
|
Through study completion, an average of 12 months
|
Service Improvement Metrics: reach
Time Frame: Through study completion, an average of 12 months
|
Spread of implementation.
Whether the intended audience comes into contact with the intervention, and how: Number of wards with 'eligible' patients and number of wards where the service is implemented.
|
Through study completion, an average of 12 months
|
Heath resource use
Time Frame: Through study completion, an average of 12 months
|
Use of health resource during the study
|
Through study completion, an average of 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PHTech questionnaire
Time Frame: Through study completion, an average of 3 months
|
Attitudes and feelings towards technology: Technophilia/Technophobia. six items in the two factors, techEnthusiasm and techAnxiety, 1 to 5 scale so that the TechPH index could be interpreted on a five-point response scale, ranging from 1 (fully disagree) to 5 (fully agree), where the higher the index indicates a higher level of technophilia.
|
Through study completion, an average of 3 months
|
Volunteer Motivation (VFI)
Time Frame: Baseline
|
A 30-item measure of motivations to volunteer.
Respondents answer each item on a 7-point scale ranging from 1 (not at all important/accurate) to 7 (extremely important/accurate).
|
Baseline
|
Age
Time Frame: Baseline
|
Age of participant measured in years
|
Baseline
|
Sex
Time Frame: Baseline
|
Sex of the participant
|
Baseline
|
Educational level
Time Frame: Baseline
|
Maximun educational level completed of the participant
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SR20-00841
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Palliative Care
-
Azienda Usl di BolognaIRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPalliative Care | Palliative Medicine | Hospice and Palliative Care NursingItaly
-
Mayo ClinicCompletedPalliative Care | Transitional CareUnited States
-
University of NottinghamCompletedPalliative Care | Long-Term CareUnited Kingdom
-
Ankara Yildirim Beyazıt UniversityRecruiting
-
University Hospital, CaenRecruitingPalliative CareFrance
-
University of PennsylvaniaNational Institute on Aging (NIA)Enrolling by invitationPalliative CareUnited States
-
Technische Universität DresdenUniversity Hospital DresdenCompletedPalliative CareGermany
-
Bispebjerg HospitalOdense University Hospital; Rigshospitalet, Denmark; Danish Cancer Society; Nordsjaellands... and other collaboratorsCompletedPalliative CareDenmark
-
University of GuadalajaraCompleted
Clinical Trials on ITV-Pal
-
Centre Leon BerardCREATIS LaboratoryCompletedNon-small Cell Lung Cancer | Radiation Therapy | Locally Advanced Disease | Non-metastatic Disease | Non-resectable DiseaseFrance
-
University Hospital HeidelbergRecruitingHepatic MetastasisGermany
-
Hywel Dda Health BoardWelsh Government; Bond Digital Health Ltd.; Bevan CommissionCompleted
-
University of Colorado, DenverNational Institute on Aging (NIA)CompletedChronic Conditions, MultipleUnited States
-
Stryker OrthopaedicsTerminatedArthroplasty, Replacement, HipUnited States
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
US Department of Veterans AffairsAbbott Diagnostics Division; Pan American LaboratoriesCompleted
-
Nationwide Children's HospitalCerebral Palsy AllianceCompletedInfarction | Thrombosis | Intraventricular Hemorrhage | Neonatal Encephalopathy | Infant Development | Hydrocephalus | Infant,Premature | PVLUnited States
-
Quadram Institute BioscienceUnilever R&D; Clinical Research and Trials Unit (Norfolk & Norwich University...Completed
-
University of Alabama, TuscaloosaRecruitingPhysical Activity | Psychosocial StressorsUnited States